

Dr. Giacino is the Director of Rehabilitation Neuropsychology and Research Associate in the Department of Physical Medicine and Rehabilitation at Spaulding Rehabilitation Hospital in Boston, Massachusetts, consulting neuropsychologist in the Department of Psychiatry at Massachusetts General Hospital, Associate Professor in the Department of Physical Medicine and Rehabilitation at Harvard Medical School and Adjunct Professor at the MGH Institute of Health Professions.

Dr. Giacino's clinical and research activities are centered on the development and application of novel assessment and treatment methods for individuals with severe acquired brain injury (ABI) and disorders of consciousness (DOC). He served as co-chair of the Aspen Workgroup (responsible for developing the diagnostic criteria for the *minimally conscious state* (MCS) and was co-lead author of the Mohonk Report, which provided recommendations to the U.S. Congress for lifelong care of patients with DOC.

He currently chairs the Disorders of Consciousness Guideline Development Panel, co-sponsored by the American Academy of Neurology, American Congress of Rehabilitation Medicine and National Institute on Disability and Rehabilitation Research, which is charged with revising existing clinical guidelines for management of patients with DOC. He serves as co-chair of the International Traumatic Brain Injury Common Data Element Steering Committee convened by the National Institute on Neurologic Disorders and Stroke to harmonize data collection across federally-funded TBI research studies.

Dr. Giacino is currently Project Director of the Spaulding-Harvard TBI Model System funded by the National Institute on Disability and Rehabilitation Research (NIDRR) and Co-PI of the NIH-funded Transforming Research and Clinical Knowledge in TBI project which will design and test a new platform of clinical, imaging, genomic and outcome biomarkers to enable more precise TBI diagnosis, prognosis and treatment.

He has served as Principal Investigator on 4 different NIDRR-funded projects- three focusing on the development of novel fMRI paradigms for detection of conscious awareness in patients with DOC, and a recently-completed 12-site clinical trial which demonstrated that amantadine hydrochloride (AH) accelerates recovery in patients with prolonged disturbance in consciousness. He was also Co-PI of an FDA-approved pilot study of deep brain stimulation aimed at restoring speech and motor functions in patients with chronic post-traumatic MCS.

Regarding clinical activities, Dr. Giacino directs the Spaulding Rehabilitation Network Disorders of Consciousness Program and maintains numerous local, national and international collaborations aimed at improving care for patients with DOC.